https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

polypharmacy
News

This Week in HIV Research: The Menace of Concomitance

April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.

taking a pill
Features

Why Do Researchers Think HIV Meds Might Work Against COVID-19?

At least one such drug still holds that promise against coronavirus, but in general there’s little precedent for the same drug blocking different viruses.

lab testing
News

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

many one dollar bills
News

This Week in HIV Research: As Pill Burden Drops, Pill Cost Rises

Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.

two elderly people sitting and looking at water
News

This Week in HIV Research: Our Attunement to Aging

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

Peter Staley Brenda Emily Goodrow and Mark Lemley credit Ivy Arce
Interviews

Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case

The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.

strips of paper with headlines over microscope science background
Features

Top 10 HIV Clinical Developments of 2019

Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.

The DAWNING Study photo illo
Features

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

hole in a fence
News

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.